Meds & supplements › Fremanezumab
Medicine
AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
AJOVY is indicated for:
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.
sofidex [Internet]. Daloreum; c2026. Fremanezumab; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/fremanezumab
sofidex. (2026, August 2). Fremanezumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/fremanezumab
Fremanezumab. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/fremanezumab
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.